Back to School: How biopharma can reboot drug development. Access exclusive analysis here

CETi-1: Phase I; Phase II

In a dose-ranging, placebo-controlled U.S. Phase I trial in 36

Read the full 109 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE